➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Express Scripts
McKinsey
AstraZeneca
Merck

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: RE42376

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent RE42376 protect, and when does it expire?

Patent RE42376 protects BOSULIF and is included in one NDA.

Summary for Patent: RE42376
Title:Substituted 3-cyanoquinolines
Abstract: This invention provides compounds of formula I having the structure ##STR00001## wherein G.sub.1, G.sub.2, R.sub.1, R.sub.4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.
Inventor(s): Wissner; Allan (Ardsley, NY), Tsou; Hwei-Ru (New City, NY), Berger; Dan M. (New City, NY), Floyd, Jr.; Middleton B. (Suffern, NY), Hamann; Philip R. (Thiells, NY), Zhang; Nan (Bayside, NY), Frost; Philip (Morris Township, NJ)
Assignee: Wyeth Holdings Corporation (Madison, NJ)
Application Number:12/785,269
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent RE42376

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-001 Sep 4, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-003 Oct 27, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-002 Sep 4, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Dow
AstraZeneca
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.